Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of August 2025
Date Filed: August 15, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document does not contain a financial statement or specific financial data points for the reporting period.
Material Changes
The filing does not disclose material changes in financial position or operations compared to prior periods. The primary disclosure is the submission of an exhibit regarding unquoted securities.
Guidance, Outlook, and Risks
Management Commentary: None provided in this filing.
Exhibits: Exhibit 99.1 contains a "Notification regarding unquoted securities - ATH".
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Risks: No specific risks or contingencies are detailed in the text of this summary filing.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 to understand the details of the unquoted securities notification.
- Verify the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential capital raising activities.
- Confirm the company's current cash runway and burn rate, as this filing does not provide updated financial metrics.
- Check for subsequent filings that may contain detailed financial results or operational updates.